Looking for practical insights on managing CIDP? Listen to the Navigating CIDP podcast, hosted by Mark Stettner, to hear expert discussions on key diagnostic considerations and therapeutic strategies. Available on Medthority's Rare Disease Nexus ow.ly/EZOG50YNX3h

📰 It’s News‑day Tuesday! Early lab research suggests gene‑editing techniques could one day help address the extra chromosome in Down syndrome. Plus, proof‑of‑concept studies show immune cells can be engineered to produce rare protective antibodies ow.ly/5AzF50YNqAn

Anita D’Souza returns in the latest episode of our #PodcastSeries, Navigating AL Amyloidosis, to discuss individualizing treatment in AL amyloidosis, from covering prognostic biomarkers to response assessment and tailored clinical decision‑making. Available now ow.ly/r4fR50YMJ8w

To mark #InternationalPompeDay, new survey data highlight persistent challenges in late‑onset Pompe disease care, from delayed diagnostic journeys to unmet supportive needs. Read the latest insights ow.ly/MWZ550YJQ4i

This #InternationalPompeDay, watch Benedikt Schoser, Priya Sunil Kishnani, and Tahseen Mozaffar discuss unmet needs in late‑onset Pompe disease, now available on the NEW Medthority Rare Disease Nexus for expert insights and CME ow.ly/48j650YJNVg

📰It’s News‑day Tuesday! A novel brain‑stimulation procedure with psychotherapy significantly reduced symptoms in soldiers and veterans with combat‑related PTSD. Plus, research highlights sex‑specific differences in brain changes in Alzheimer’s disease ow.ly/WZaN50YIMIB

From standards of care to emerging treatment strategies, Ashish Kamat and Joshua Meeks discuss how clinicians approach non‑muscle‑invasive bladder cancer in real‑world practice today🎧 ow.ly/ZMqw50YH36B #BladderCancer #MedicalEducation #Oncology

What questions do people with myasthenia gravis (MG) rarely ask – but clinicians should? 🎥 John Vissing highlights practical, patient‑centred questions to uncover symptom burden, fatigue, mental health, and treatment expectations in everyday MG care ow.ly/Wp2y50YGCGr

📰It's News‑day Tuesday! Surgery for early‑stage lung cancer may be safe and effective in patients over 80. Plus, poison control data reveal a sharp rise in kratom‑related overdoses in the U.S #MedSky #MedicalNews #MedEd ow.ly/hHkq50YF2RG

🌍 World Health Day Access trusted, independent medical education this #WorldHealthDay. Medthority supports healthcare professionals with free, on‑demand resources, developed with leading experts to inform practice and improve patient care ow.ly/86MJ50YEVpC

📰 It’s News‑day Tuesday! A newly-identified brain biomarker linked to schizophrenia could support more targeted treatments. Plus, researchers report early success using a virus to combat antibiotic‑resistant Salmonella ow.ly/76PO50YBgki #MedEd #MedSky #medicaleducation

Ending #EndometriosisAwarenessMonth by spotlighting new research that could help identify cases missed by imaging. Read more below 👇 #Endometriosis #MedEd

What do you think about Medthority? Tell us about your experience so far and what you’d like to see next. Your feedback helps us build better #medicaleducation for busy healthcare professionals like you ow.ly/poZ350YzchT

Listen to our NEW Navigating CIDP podcast series, now available on demand with Medthority. Join Mark Stettner, Luis Querol, and Filip Eftimov as they discuss the evolving challenges of diagnosing and managing #CIDP in real-world practice ow.ly/yOEi50YyLme

📰 It’s News‑day Tuesday! A new blood test may improve detection of endometriosis, identifying cases missed by imaging. Plus, early trial data suggest a novel oral approach could improve function in people living with ALS ow.ly/LE5050Yy2o6 #MedSky #MedicalNews #MedEd

Navigate secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) with insights from experts in our on-demand podcast series. Hear Michael Jordan, and expert guests discuss evolving treatments and diagnostic challenges 🎧 ow.ly/Tr5b50YxYLF

Heading to #THSNA2026? Which VTE trial do you think had the biggest impact in 2025 and why? Hear expert perspectives from Geoffrey Barnes, Marc Carrier, Edelgard Lindhoff-Last, and Marco Proietti in this roundtable discussion, free and on-demand ow.ly/iQeu50YvVvl

📰 It’s News‑day Tuesday! Dementia‑related deaths are rising among people with type 2 diabetes, despite declines in cardiovascular mortality. Plus, low testosterone may signal which patients with prostate cancer need closer active surveillance ow.ly/oAUq50YviFA

Gain insights on early multi-system clues in #AATD and how emerging RNA and gene-based therapies could shape future care. Jorge Lascano and Gerry McElvaney share guidance on coordinated lung–liver management and evolving treatment pathways ow.ly/T0NF50YvgSW

Listen to the latest episode of Unlocking Myasthenia Gravis to hear Nils Erik Gilhus and Gil Wolfe discuss thymectomy in #MyastheniaGravis, covering patient selection, age considerations, and evolving treatment strategies Available now on Medthority ow.ly/RVHv50YsrEC

📰 It’s News‑day Tuesday! New research links a Parkinson’s‑related protein to faster Alzheimer’s progression in women. Plus, an experimental therapy shows promising seizure reduction in children with a rare genetic epilepsy ow.ly/pgIS50YrLf4 #MedEd #MedSky

Catch up with the latest episodes of our #PodcastSeries as Shaji Kumar is joined by Taxiarchis Kourelis and Vaishali Sanchorawala to discuss practical steps in recognizing #ALAmyloidosis early, plus emerging modalities that may impact standard care ow.ly/Yt1I50Yrrkr

Read the latest insights from #GU26 From genomic predictors to real‑world combination strategies, experts highlight TP53 status as a potential marker of benefit, broad activity across disease features, and evolving mCRPC approaches ow.ly/tuHe50Ypb0U #ASCOGU #ASCOGU2026 #MedEd #MedSky

It’s News‑day Tuesday! Does intensifying treatment improve outcomes? At #GU26, Karim Fizazi unpacks first PEACE‑2 results—finding no clinical benefit beyond long‑term ADT + radiotherapy in very high‑risk localized prostate cancer ow.ly/sQ9G50Yoxrz

What’s holding back routine HRR testing in #ProstateCancer care? Watch Arun Azad unpack common misconceptions, real‑world workflow challenges, and why education is critical to ensuring patients don’t miss access to PARP inhibitors. ow.ly/lbgr50Yoatp #MedEd #Oncology #MedSky

That’s a wrap for this oral abstract session on IMvigor011 trial at #GU26 Missed any insights? Explore on demand congress coverage and expert perspectives on Medthority ow.ly/zJpy50Yn3UP

Dr. Bellmunt concludes IMvigor011: 🧬 Detectable ctDNA after RC identified higher‑risk pts, while persistent ctDNA− aligned with low risk 💉 Adjuvant atezolizumab promoted ctDNA reduction and clearance which was associated with improved DFS #GU26 #BladderCancer #MIBC

🔬 Dr. Bellmunt presents IMvigor011: early ctDNA positivity after RC was frequent and typically detected within <24 wks 📉Baseline ctDNA levels differed by risk group, and ctDNA kinetics showed clear divergence between arms over time #GU26 #BladderCancer #MIBC #Oncology

Can ctDNA timing and dynamics refine adjuvant treatment decisions in #MIBC? Follow our #GU26 coverage for new insights from Joaquim Bellmunt on the IMvigor011 trial #BladderCancer #Oncology #MedSky #MedEd

That concludes our live coverage on the KEYNOTE-B15 trial. Stay tuned for the oral abstract session on the IMvigor011trial starting at 16:57 BST/08:57 PST 🕔

Matthew D. Galsky concludes neoadjuvant + adjuvant EV+pembro improved EFS, OS and pCR vs cis+gem in cisplatin‑eligible MIBC 📈 Efficacy appeared consistent across subgroups and no new safety signals were seen Findings support EV+pembro as a novel option in MIBC #GU26 #BladderCancer

KEYNOTE‑B15: EV + pembro shows strong EFS benefit in cisplatin‑eligible MIBC HR 0.52; 12‑mo EFS 78.2% vs 64.0% with chemo Matthew D. Galsky notes “The EV+pembro and cis+gem curves separate at ~6 months and stay apart” ✅EFS significantly longer with EV+pembro #GU26 #Oncology #MIBC

We’re back with more #GU26 coverage! Today we kick-off with the latest results from the KEYNOTE-B15 study presented by Matthew D. Galsky #BladderCancer #Oncology #MIBC #MedEd #MedSky

That wraps up our live coverage of #GU26 sessions on #mCRPC! From PEACE‑3 to BRCAAway, today’s discussions highlighted how combination strategies are reshaping overall survival in #mCRPC For more congress coverage, visit the Prostate Cancer Nexus on Medthority ow.ly/yCG750YmtgI

Key takeaways from BRCAAway: 🔹 A + O showed longest OS (46.2 mo) 🔹 Strongest 24‑ & 36‑mo OS landmarks 📈 🔹 AEs manageable; A + O maintained acceptable tolerability 🔹 Supports continued evaluation of PARPi + ABI in DDR‑mutated mCRPC #GU26 #mCRPC #ProstateCancer #Oncology

Dr. Hussain presents OS results from the BRCAAway trial in first‑line #mCRPC with DDR defects: 🔹 Abiraterone, olaparib, or the combination in BRCA1/2/ATM 🔹 Median OS longest in Arm 3 (A+O): 46.2 mo 🔹 Arm 3 showed highest 24 & 36‑mo OS 📊 #GU26 #ProstateCancer #Oncology

What’s next for overall survival optimization in #mCRPC? Following the PEACE‑3 final OS results with enzalutamide + radium‑223 from Enrique Gallardo, the conversation continues with Maha HA Hussain and the BRCAAway OS data at #GU26.

🗝 Key takeaway points from PEACE‑3: 📈 ENZA + 6 cycles Rad‑223 improves OS ⚠️ No new safety signals; moderate AE increase 💊 “ENZA + Rad‑223 (with BPA) is an option in first‑line mCRPC with bone metastases” #GU26 #Oncology #MedEd #mCRPC #ProstateCancer #MedSky

Dr. Gallardo shares final data from PEACE‑3 (Enzalutamide ± Radium‑223) in mCRPC with bone mets: 🔹 Significant OS benefit with ENZA + Rad‑223 🔹 rPFS improvement confirmed 📈 🔹 Moderate ↑ in AEs #GU26 #mCRPC #ProstateCancer #Oncology

How have combination strategies reshaping overall survival in #mCRPC? Join our #GU26 coverage as Enrique Gallardo and Maha HA Hussain discuss the latest overall survival results from the EORTC 1333/PEACE‑3 and BRCAAway trials. #ProstateCancer #Oncology #OncTwitter #MedEd #MedSky

We're at #GU26! Stay informed on the latest research in #ProstateCancer and #BladderCancer with our live coverage from the event, plus keep an eye out for summary articles, free and on demand with Medthority 👀 #MedSky #ASCO #ASCOGU ow.ly/HUNu50Ymiw3

📰 It’s News-day Tuesday! Scientists uncover how low‑oxygen conditions turn red blood cells into “glucose sponges,” opening the door to new diabetes treatments. Plus, new research shows brain cells are key to building exercise endurance. #MedEd #MedSky ow.ly/MgWz50YkTk0

Stronger PSA suppression leads to improved outcomes in mHSPC, new study finds. Read our summary article on Medthority now for more insights on how this simple biomarker can have powerful prognostic value #MedSky #ProstateCancer #MedEd ow.ly/QFbL50Ykebx

📰 It’s news‑day Tuesday! A new experimental drug has doubled survival for women with treatment‑resistant ovarian cancer in a recent trial. Plus, AI shows promise in detecting placenta accreta spectrum, a dangerous pregnancy complication. #MedEd #MedSky ow.ly/2sXH50YgWmi

New insights from #WORLDSymposia 2026 are shaping how we think about #LysosomalDiseases. Our latest research update explores how early biomarker and symptom patterns in newborn‑screened infants may help guide #PompeDisease treatment decisions #MedSky ow.ly/5X7Q50YgCLc

This #InternationalDayOfWomenAndGirlsInScience, we want to celebrate our exceptional all-female writing team! With experience across all 15 specialties, they help us bring you closer to the conversations that matter in your field #MedSky #MedEd #WomenInSTEM ow.ly/6lKv50YcJIf

📰 It's News-day Tuesday! Women vaccinated against HPV need fewer cervical cancer screenings in their lifetime, plus new data reveals the impact of the COVID-19 pandemic on cancer survival in the US. Read the latest #MedicalNews now on Medthority #MedSky #MedEd ow.ly/ksA150Yc70t

If you enjoyed #ACTRIMSForum 2026 over the weekend, why not review our resources on multiple sclerosis (MS) to catch up with the guideline updates and latest news you need to know #MedSky #ACTRIMS #MS #MultipleSclerosis #MedEd ow.ly/Fb7650YbGNV

This #WorldCancerDay, browse our Oncology Hub for the latest advances and congress highlights in genitourinary, respiratory, and sarcoma oncology, from assessing patient risk of disease recurrence to identifying unmet needs #MedSky #MedEd #OncSky ow.ly/U6hj50Y8SXr

📰It's news-day Tuesday! Colon cancer has become the leading cause of cancer-related deaths in American adults under 50. Plus, can exposure to wildfire smoke during pregnancy increase the risk of an autism diagnosis? #MedSky #MedicalNews #MedEd ow.ly/Ms4T50Y823b